Pazopanib plus cetuximab in recurrent or metastatic head and neck squamous cell carcinoma: an open-label, phase 1b and expansion study

BACKGROUND: Angiogenesis is a hallmark of head and neck squamous cell carcinoma (HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety and potential activity of pazopanib, an angiogenesis inhibitor, plus cetuximab, an EGFR inhibitor, in patients with recurrent or metas...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Lancet Oncol
Main Authors: Adkins, Douglas, Mehan, Paul, Ley, Jessica, Siegel, Marilyn J, Siegel, Barry A, Dehdashti, Farrokh, Jiang, Xuntian, Salama, Noha N, Trinkaus, Kathryn, Oppelt, Peter
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6561471/
https://ncbi.nlm.nih.gov/pubmed/30001987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30350-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki